Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C162878
http://purl.obolibrary.org/obo/NCIT_C162878
|
|---|---|
| Preferred Name | Lenalidomide Analog KPG-121 |
| Definitions |
A lenalidomide analog with potential anti-angiogenic and immunomodulatory activities. Upon oral administration, lenalidomide analog KPG-121 may inhibit tumor necrosis factor alpha (TNF-alpha) production, stimulate T-lymphocytes, reduce serum levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF; FGF2), and inhibit angiogenesis. Additionally, KPG-121 may promote G1 cell cycle arrest and induce apoptosis in malignant cells.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A lenalidomide analog with potential anti-angiogenic and immunomodulatory activities. Upon oral administration, lenalidomide analog KPG-121 may inhibit tumor necrosis factor alpha (TNF-alpha) production, stimulate T-lymphocytes, reduce serum levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF; FGF2), and inhibit angiogenesis. Additionally, KPG-121 may promote G1 cell cycle arrest and induce apoptosis in malignant cells. |
|---|---|
| prefLabel | Lenalidomide Analog KPG-121
|
| label | Lenalidomide Analog KPG-121
|
| NCI_META_CUI | CL973359
|
| PDQ_Closed_Trial_Search_ID | 798954
|
| code | C162878
|
| prefixIRI | NCIT:C162878
|
| in_subset |
See more
See less
|
| Display_Name | Lenalidomide Analog KPG-121
|
| Preferred_Name | Lenalidomide Analog KPG-121
|
| Contributing_Source | CTRP
|
| Maps_To | Lenalidomide Analog KPG-121
|
| NCI_Drug_Dictionary_ID | 798954
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 798954
|
| Semantic_Type | Pharmacologic Substance
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |